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ABSTRACT
Introduction Preserving residual kidney function (RKF) 
may be beneficial to patients on haemodialysis (HD) 
and it has been proposed that commencing dialysis 
incrementally rather than three times a week may 
preserve RKF. In Incremental HD, target dose includes a 
contribution from RKF, which is added to HD dose, allowing 
individualisation of the HD prescription. We will conduct 
a feasibility randomised controlled trial (RCT) comparing 
incremental HD and conventional three times weekly 
treatments in incident HD patients. The study is designed 
also to provide pilot data to allow determination of effect 
size to power a definitive study.
Methods and analysis After screening to ensure native 
renal urea clearance >3 mL/min/1.73 m2, the study will 
randomise 54 patients within 3 months of HD initiation 
to conventional in- centre thrice weekly dialysis or 
incremental in- centre HD commencing 2 days a week. 
Subjects will be followed up for 12 months. The study will 
be carried out across four UK renal centres.
The primary outcome is to evaluate the feasibility 
of conducting a definitive RCT and to estimate the 
difference in rate of decline of RKF between the two 
groups at 6 and 12 months time points. Secondary 
outcomes will include the impact of dialysis intensity on 
vascular access events, major adverse cardiac events 
and survival. Impact of dialysis intensity on patient- 
reported outcomes measures, cognition and frailty will be 
assessed using EQ- 5D- 5L, PHQ-9, Illness Intrusiveness 
Rating Score, Montreal Cognitive assessment and Clinical 
Frailty Score. Safety outcomes include hospitalisation, 
fluid overload episodes, hyperkalaemia events and 
vascular access events.
This study will inform the design of a definitive study, 
adequately powered to determine whether RKF is better 
preserved after incremental HD initiation compared with 
conventional initiation.
Ethics and dissemination Ethics approval has been 
granted by Cambridge South Research Ethics Committee, 
United Kingdom(REC17/EE/0311). Results will be 
disseminated via peer- reviewed publication.
Trial registration number NCT03418181
BACKGROUND
Most patients with end- stage renal failure have 
a degree of native kidney function (residual 
kidney function, RKF) remaining when they 
initiate haemodialysis (HD). There has been 
recent interest in incremental HD, a method 
of individualising HD according to the level of 
RKF to permit dialysis to be commenced at a 
lower intensity than conventional approaches 
allow. Most patients commence dialysis using 
conventional three times weekly dialysis with 
RKF usually not accounted for in prescribing 
dialysis dose. In Incremental HD, RKF is 
combined with dialysis clearance to provide 
an overall measure of solute removal allowing 
the dose provided by dialysis to be individ-
ualised. Various algorithms are available to 
assist with this such as Standard Kt/V (Std 
Kt/V), which includes contributions from 
both Std Kt/VRKF and Std Kt/Vdialysis.
1–3 In this 
approach, reduction of dialysis dose may be 
considered provided that the combined urea 
Strengths and limitations of this study
 ► There are no randomised studies comparing incre-
mental haemodialysis (HD) and conventional three 
times weekly treatments in incident HD patients. 
This study will address this gap.
 ► It will provide data on feasibility of recruitment to 
a definitive study together with an estimate of the 
effect size of group differences in rate of loss re-
sidual kidney function (RKF) allowing sample size 
calculation.
 ► Impact and intrusiveness of dialysis intensity will 
also be compared between groups.
 ► The sample size will not permit definitive determi-
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clearance targets are met and other markers of dialysis 
adequacy such as blood pressure, interdialytic weight 
gains, anaemia, potassium, phosphate control, nutri-
tion and general well- being are not compromised. The 
technique requires that the proportion of target dose 
provided by dialysis is increased as the RKF declines or if 
there are any other indicators for inadequate dialysis. The 
dialysis team and patients need to be aware of the impor-
tance of regular measurement of RKF 1–3 monthly.4 This 
incremental approach may not be suitable for patients 
who are unable or unwilling to collect urine samples.
Traditionally RKF has been incorporated into peri-
toneal dialysis dosing but it has not been included in 
calculating HD dose due to limited practical experiences 
and outcome data from clinical studies. There are no 
randomised controlled trials (RCTs) that compare clin-
ical outcomes of incremental HD and those of conven-
tional thrice- weekly HD. A number of observational 
studies have compared clinical outcomes of twice- weekly 
HD and conventional thrice- weekly HD regimens.5–19 
These studies suggest that the mortality risks and survival 
outcomes are not inferior in those on the twice weekly 
dialysis regimen compared and those treated convention-
ally, provided there is adequate RKF. Importantly, several 
non- randomised studies have suggested that RKF is better 
preserved in those dialysed twice weekly commencing 
soon after dialysis initiation.6 10 11 17 18 Preservation of RKF 
may provide clinical benefits to HD patients including 
better fluid control, significant solute and fluid removal. 
It is also associated with improved quality of life and 
survival.
These findings indicate the need for a prospective RCT 
comparing RKF preservation following incremental and 
conventional initiation of dialysis. We are undertaking a 
study to determine the feasibility of conducting such a 
study. Our study will also provide pilot data to estimate 
differences in the rate of decline of RKF in the first year 
after commencing dialysis using either conventional or 
incremental approaches. The primary outcome of our 
study is to evaluate the feasibility of conducting an RCT 
in patients who have recently started HD. Patients will 
be randomised either to an incremental arm initiating 
with twice weekly dialysis or to a conventional three times 
weekly dialysis. Our study will explore key methodolog-
ical, design and safety issues, and also estimate an effect 




The trial is sponsored by East and North Hertfordshire 
National Health Service (NHS) Trust. The University of 
Hertfordshire Clinical Trial Support Network (CTSN) 
will provide independent support for randomisation and 
monitoring of the study. The conduct of the trial will be 
overseen by a Steering group which will meet regularly 
and will include an independent chair and coapplicants. 
The CTSN will monitor compliance with the study 
protocol at 3 months following study initiation and then 
as required by sponsor scrutiny of data returns.
Ethics and dissemination
The study received ethical approval from East of England—
Cambridge South (REC reference 17/EE/0311; IRAS 
project ID 219032). Study endpoints, whether negative or 
positive, will be published with the intention of reaching 
a wide audience in nephrology both in peer- reviewed 
publication and also submitted for presentation at inter-
national and UK meetings including the British Renal 
Society Conference. Following publication of final data 
an anonymised data set will be made available on request.
Patient and public involvement
A summary of the initial protocol was shared with 10 
patients who were asked to comment on the study design, 
the potential willingness of patients to participate in the 
study and the burden of study procedures and interven-
tions. Their comments were taken account of in preparing 
the final version of the protocol. Patients will be involved 
in interpreting study finding and in design of definitive 
study. We will report a summary of results to patients in a 
personal communication by mail. We will also summarise 
results to local patient association newsletters.
Setting
The study will take place in four NHS Trust renal units—
East and North Hertfordshire, Royal Free Hospitals, Royal 
Berkshire Hospitals and University Hospitals of Leicester. 
The total number of participants from all centres will 
be 54. Recruitment commenced in January 2018 and 
completion of follow- up will be in May 2020.
Study objectives and end points
The study’s primary objective is to determine the feasi-
bility of conducting a definitive RCT of incremental HD 
initiation, compared with conventional thrice weekly 
in- centre HD initiation. There are a number of aspects to 
this primary objective which are summarised in table 1. 
We will determine, at each study site, the proportion of 
incident HD patients it is practical to approach, who 
prescreen as suitable for formal study screening (eligibility 
for screening). We will determine the proportion of those 
patients who consent undergo formal screening, pass the 
screening test and are randomised (recruitability). We 
will also determine the study retention rate (retainability) 
as well as fidelity to the protocol (protocol adherence) 
of patients in the study. Numerators and denominators 
for these parameters are shown in figure 1. The study 
will establish evidence for the safety of the incremental 
approach. It will also generate data allowing estimation of 
the effect size of the difference in rate of decline of RKF 
in the 6 months following randomisation between incre-
mental and conventional HD arms.
Secondary objectives of the study are to determine 
whether there is a signal of benefit for incremental HD 
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function, illness intrusiveness, functional status, frailty, 
risk of vascular access failure or interventions, major 
adverse cardiac events (MACEs) and survival. Specific 
tools used and methods to measure secondary outcomes 
related to these secondary objectives are detailed in 
table 1. Illness intrusiveness will be measured with the 
Illness Intrusiveness Rating Scale (IIRS), a validated tool 
to measure impact of the dialysis treatment and disease 
on physiologically meaningful activity and its psychosocial 
impact.20 Quality of life will be measured using EQ- 5D- 5L, 
a validated tool which will capture different dimensions 
of quality of life including anxiety/depression and pain/
discomfort and can be used in health economic evalu-
ation.21 Cognitive function will be measured using the 
Montreal Cognitive Assessment (MoCA) which is a tool 
for assessment of cognitive function that has been vali-
dated in dialysis patients against detailed neurophysio-
logical testing covering different domains of cognitive 
function and provides good sensitivity and specificity for 
identifying cognitive impairment in this population.22 23 
Clinical frailty will be measured using the Clinical Frailty 
Score (CFS).24 25
Participants
All adult patients who have commenced HD in the 
previous 3 months will be considered for the study. 
Those who potentially meet the eligibility criteria after 
prescreening by review of medical records including 
the requirement for a standard of care interdialytic urea 
clearance ≥3 mL/min/1.73 m2 Body Surface Area (BSA) 
will eligible for study screening. Those consenting for the 
study will undergo formal screening to include confir-
mation of their meeting the eligibility criteria including 
having an interdialytic urea clearance ≥3 mL/min/1.73 
m2 BSA on retesting.
Consent
Consent will be required prior to screening procedures 
and will include agreement to screening which includes 
confirmation of urea clearance ≥3 mL/min/1.73 m2 
BSA and an explicit consent to a protocol- driven dialysis 
regimen and to randomisation to incremental HD or 
standard thrice weekly HD arms.
Inclusion criteria:
 ► Age ≥18 years.
 ► Advanced kidney failure—established as a new starter 
on HD within the previous 3 months.
 ► RKF likely to permit twice weekly dialysis as defined 
by interdialytic urea clearance ≥3 mL/min/1.73 m2 
BSA measured routinely as part of standard care or as 
prescreening.
 ► Sufficient understanding of the study procedures and 
requirements including capacity for explicit agree-
ment to be randomised to standard or incremental 
HD regimens.
Table 1 Study objectives
Primary objective Primary outcome
The proportion of eligible subjects agreeing to participate 
in the study—Recruitability
 ► Proportion incident HD patients it is practical to approach, who prescreen as 
suitable for screening (eligibility for screening).
 ► Proportion of screened patients who fulfil all eligibility criteria for participation 
in the study.
 ► Proportion of these patients who agree to participate in the study.
The proportion of randomised subjects who remain in the 
study—Retainability
Proportion of patients randomised who remain in the study excluding study 
withdrawals, and reasons for withdrawals.
The proportion of subjects who adhere to protocol- driven 
changes in dialysis frequency—Protocol adherence
Proportion of patients who adhere to protocol dialysis frequency.
The number of adverse and serious adverse events—
Safety of the study
Frequency of hospital admission due to hyperkalaemia and fluid overload, and 
lower respiratory tract infection.
An estimate of the effectiveness of the intervention—
Effect size
 ► Dialysis dose and RKF as measured by Std Kt/V.
 ► Rate of change (mean) of RKF in the first 6 and 12 months after randomisation.
Secondary objectives Secondary outcome
Retention of RKF Proportion of patients with interdialytic urea clearance ≥2 and ≥3 mL/min/1.73 m2 
at 6 months.
Quality of life (QOL) QOL is assessed using EQ- 5D- 5L questionnaire.
Mood—depression Depression assessed using PHQ-9 questionnaire.
Cognitive function Change in cognitive function as assessed by MOCA tool.
Illness intrusiveness Illness intrusiveness is assessed using Illness Intrusiveness Rating Scale.
Functional status/frailty Functional status assessed by Clinical Frailty Score.
Vascular access failures or problems Frequency of vascular access failures and interventions.
Major adverse cardiac events (MACE) MACE is assessed by recording of the frequency of the events.
Survival Survival is measured by all- cause mortality.
EQ- 5D- 5L, EuroQol EQ- 5D- 5L questionnaire; HD, haemodialysis; MOCA, Montreal Cognitive assessment; PHQ-9, Patient Health Questionnaire, 9 
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Exclusion criteria
 ► Planned organ transplantation within 3 months from 
study screening.
 ► Anticipated requirement for high- volume ultrafil-
tration on dialysis (eg, subjects with daily enteral or 
parenteral nutrition)
 ► Bloodborne virus positivity.
 ► Subjects unable to comply with requirement for 
monthly interdialytic urine collection.
 ► Pregnancy.
 ► Prognosis <12 months as judged by the principal 
investigator.
Screening phase
At screening inclusion and exclusion criteria will be 
confirmed. Confirmation of interdialytic urea clearance 
≥3 mL/min/1.73 m2 BSA will be performed. Pregnancy 
test will be performed in females of childbearing age 
to reduce chance of unexpected pregnancy occurring 
during the study which would require study withdrawal. 
Patients who, at screening, are eligible for study partic-
ipation according to eligibility criteria, and who are 
confirmed to have a screening inter- dialytic urea clear-
ance ≥3 mL/min/1.73 m2 BSA will eligible for rando-
misation. Subjects who fail screening will be eligible for 
rescreening 1 month later provided their screening urea 
clearance is >2 mL/min/1.73 m2 BSA and the rescreening 
time point remains within 3 months of dialysis initiation. 
At rescreening, a urea clearance ≥3 mL/min/1.73 m2 
BSA will be required for randomisation into the study.
Randomisation
Web- based randomisation will be carried out by each 
centre using Qualtrics, supported by the CTSN, Univer-
sity of Hertfordshire. Subjects will be randomised on a 
1:1 basis to each study arm and each subject allocated a 
unique study ID.
Figure 1 Flow diagram of clinical trial demonstrating data that will be used to calculate eligibility for screening, screen failure 
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Study phase
Following randomisation, study subjects will be dialysed 
according to the protocol of their randomisation arm as 
per the schematic in figure 1. Monthly quality assessment 
of dialysis in both arms will include a measure of dialysis 
clearance (Std Kt/VDialysis). RKF will be measured monthly 
by urea clearance in both arms and converted to Std Kt/
VRKF.
In the standard dialysis arm, dialysis adequacy will 
be assessed only using the Std Kt/VDialysis. In the incre-
mental dialysis arm, the adequacy will be assessed using 
a composite of dialysis clearance (Std Kt/VDialysis) and 
RKF (Std Kt/VRKF) as detailed below. This composite is 
termed Std Kt/VDialysis+RKF. HD modes will remain standard 
throughout the study. Haemodiafiltration may be used 
where blood flow >250 mL/min, otherwise high- flux HD 
will be used.
Assessment of RKF
There are two main methods of including RKF in HD 
prescription. The first converts residual urea clearance 
to an equivalent dialysis sessional clearance.7 The second 
converts sessional Kt/V to a weekly equivalent clearance. 
Both these allow the addition of dialysis and renal clear-
ances. There are two variants of the second method: Std 
Kt/V26 and the Casino- Lopez Equivalent renal urea clear-
ance (EKR).27 Both these are urea clearance based. The 
ERBP guidelines recommend use of GFR (mean of urea 
and creatinine clearance) in the EKR equation rather 
than urea clearance which was intrinsic to originally 
derived equation. We have used Std Kt/V which takes a 
more conservative view of RKF since urea clearance is 
around 30% lower than GFR. Further details of the meth-
odology for assessment of RKF can be found in online 
supplementary material 1.
Groups
Control Group: standard HD arm
Subjects in the standard HD arm will be dialysed to target 
minimum Std Kt/VDialysis of 2 per week. Subjects will be 
dialysed after randomisation initially for 3.5–4 hours 
thrice weekly. Dialysis dose will be adjusted using standard 
measures including maximising blood flow, dialysis time, 
membrane surface area and improving vascular access. 
Reduction in dialysis frequency will not be permitted.
Interventional group: incremental HD arm
Subjects randomised to the incremental HD arm will 
be dialysed to a target minimum Std Kt/VTotal (Std Kt/
Vdialysis+Std Kt/VRKF) of 2 per week. Following randomis-
ation dialysis will be initiated twice weekly, with a session 
duration of 3.5–4 hours. If Std Kt/VTotal exceeds the 
minimum target, clinicians will be permitted to reduce 
dialysis duration provided the target level is still achieved. 
If Std Kt/VTotal does not meet the target, clinicians will 
be permitted to increase dialysis dose by optimising dial-
ysis clearance (membrane selection, blood flow, vascular 
access, increasing dialysis time or frequency). Clinicians 
will also be permitted to increase the dialysis frequency to 
thrice- weekly or greater if required. The main trigger for 
this will be failure to meet minimum adequacy targets but 
clinicians will have the freedom to make this transition on 
other clinical grounds including hyperkalaemia and fluid 
overload. The reasons for switching from twice to thrice 
weekly will be recorded. Hyperkalaemia and fluid over-
load are also captured as serious adverse events (SAEs).
Deviations to study protocol
If subjects are admitted to hospital, efforts will be made 
to maintain adherence to the dialysis protocol. However, 
during admissions, modifications to the dialysis prescrip-
tion, which include increasing dialysis frequency, are 
permitted in the interests of patient safety. These will be 
recorded as protocol deviations.
In the event of subjects in the incremental HD arm 
not providing interdialytic urine samples for calculation 
of Std Kt/VRenal for two consecutive months, the subject 
will be advised to dialyse thrice weekly and will remain in 
the study with target Std Kt/VDialysis>2 (ie, assuming RKF is 
zero), until an interdialytic urine collection is provided. 
Additional study visits may be performed if necessary 
following hospital admission, holiday or non- adherence 
to treatment schedule.
Procedures to avoid loss from follow-up or study withdrawal
The patient information sheet (online supplementary 
material 2) and consent form (online supplementary 
material 3)will draw attention to the requirement for 
patients to agree that their dialysis regimen and frequency 
will be adjusted according to the study protocol.
For patients wishing to withdraw consent, the investi-
gator will explore with the patient the reasons for wishing 
to withdraw. In patients who wish to withdraw because 
they are unable to tolerate the intensity, frequency or 
duration of dialysis, the investigator will be permitted to 
offer to the patient to remain in the study with reduced 
dialysis intensity according to clinical judgement and 
record this as a protocol deviation (intention- to- treat 
approach). Patients who withdraw will be encouraged 
to remain in the study for the purpose of outcome data 
collection including measurement of RKF.
Data collection
Data will be collected by the research team members at 
baseline and then monthly thereafter for 12 months. 
Table 2 summarises study assessments during the study 
and study time points.
Measurement of dialysis adequacy
Details of the method of measuring dialysis adequacy are 
provided in online supplementary material 1. The dial-
ysis dosing adjustment will be carried out monthly using 
Std Kt/V calculated by this method. For patients dialysing 
thrice weekly (Monday/Wednesday/Friday or Tuesday/
Thursday/Saturday), the Monday/Tuesday session is 
considered to be session 1 of the week (HD1) and the 
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of the week (HD2). For patients dialysing twice weekly 
(Monday/Friday or Tuesday/Saturday), the Friday/
Saturday is considered HD1 and the Monday/Tuesday 
HD2. Blood and urine samples to be taken are shown in 
table 2 (Schedule of Events) and in figure 2. The urine 
collection and measurement of RKF is performed from 
HD1 to HD2 and will be calculated from post- HD1 and 
pre- HD2 serum urea/creatinine, urine volume and urine 
urea/creatinine concentration as per the equations in 
the online supplementary material 1. The measurement 
of dialysis dose is calculated from dialysis session data 
(preweight and postweight HD2 weight, Watson volume, 
pre- HD2 and post- HD2 urea and dialysis session duration 
(Td) (see online supplementary material 1 for calcula-
tion procedure).
Urine collection will consequently be over approxi-
mately 3 days for twice weekly patients and 2 days for thrice 
weekly patients. Although there is a small risk of bias due 
to longer duration urine collections for twice weekly HD 
patients, this is likely to be balanced by the incentive for 
these patients to provide complete urine collections to 
ensure their dialysis intensity is not increased.
Sample size
Retrospective studies suggest that decline of RKF may be 
attenuated in patients who receive twice weekly dialysis 
compared with thrice weekly, and that this effect occurs 
early such that a difference in RKF at 6 months is likely to 
be an optimal time point for the basis of a power analysis. 
Our initial power analysis, based on our own retrospec-
tive data,28 indicated an effect size (Cohen’s d) of 0.37 
calculated from mean and SD of urea clearance slopes 
Figure 2 Timing of urine collection and blood tests for 
dialysis adequacy measurement for patients on twice Weekly 
and thrice weekly HD. HD, haemodialysis.
Table 2 Schedule of events
Study period
Prescreening Baseline/screening Visit 1–12
Months −12 to 0 0 1–12
Study procedures/assessments
  Consent   X   
  Inclusion/exclusion criteria X X   
  Demographics, medical history, physical examination, height   X   
  Randomisation   X   
  Rescreening*   X   
  Concomitant medications -diuretics, erythropoietin stimulating 
agents, antihypertensive, phosphate binders
  X X
  Monthly dialysis blood tests   X X
  Monthly dialysis adequacy assessments   X X
  Pre- HD1 urea, post- HD1 urea, pre- HD2 urea, post- HD2 urea† X X X
  Inter- dialytic urine collection for urea and creatinine clearance 
measurement
  X X
  Frozen samples for β−2 microglobulin and β trace protein   X X
  Bioimpedence measurement   X X
Safety assessments
  Adverse events, serious adverse events, MACE, end points     X
Questionnaires
  EQ- 5D- 5L, IIRS, PHQ9, MoCA, CFS   Months 0, 6, 12
*Patients who fail screening will be eligible for rescreening 1 month later provided their screening urea clearance is >2 mL/min/1.73 m2 BSA 
and the rescreening time point remains within 3 months of HD initiation.
†Dialysis adequacy can be calculated using either post- HD1 urea, pre- HD2 urea, post- HD2 urea or optionally using pre- HD1 urea, post- HD1 
urea, pre- HD2 urea.
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in the first 6 months after HD initiation between two 
groups of patients, one initiating HD twice weekly and 
the other thrice weekly. Based on this, the sample size for 
the proposed definitive RCT would be 180 (90 each arm). 
If the definitive study were to be carried out using the 
same four centres, the available incident HD population 
would be around 600 annually or 1200 over a proposed 
2- year recruitment period. We anticipate that 40% of 
these patients will meet the eligibility criteria, that is, 480 
patients. To achieve 180 analysable patients at 6 months 
following randomisation, we will need to recruit 50% of 
eligible patients assuming a retention rate of 75% over 6 
months.
This feasibility study will test these assumptions on 
effect size, the proportion of incident patients who can 
be prescreened who are eligible to be approached for 
study consent, the proportion of patients approached 
for screening who consent, pass formal screening and 
undergo randomisation (recruitability), and the reten-
tion rate during the 6 months after randomisation 
(retainability). Sample sizes between 24 and 50 have 
been recommended for feasibility studies.29 30 Initially, we 
chose a sample size of 50 but, because of a higher than 
anticipated recovery of renal function in the first few 
weeks of recruitment, increased this to 54. A sample of 
this size will enable us to estimate eligibility, recruitability, 
screen- failure rate and retainabililty rate to within a 95% 
CI 11% to 14%.
AEs and SAEs
All AEs will be recorded in an AE log. SAEs will be reported 
to the CI and sponsors within 24 hours of the research 
team becoming aware of the event. For the purpose of this 
study, SAE which result in death, hospitalisation, MACE, 
infections requiring antibiotic use, episodes of fluid over-
load needing resetting of dry weight, episodes of hyper-
kalemia (potassium level >6.5 mmol/L), vascular access 
events (tunnelled line failures, tunnelled line infections, 
fistula thrombosis, fistula stenosis, false aneurysm) will be 
captured.
Data analysis
The primary outcome is to evaluate the feasibility of 
conducting an RCT comparing the effect, on RKF 
decline, of incremental and conventional approaches to 
HD initiation. The study will be analysed as intention to 
treat. In order to estimate the study power for a future 
large- scale RCT, estimates of change in RKF in the first 6 
and 12 months after dialysis initiation will be determined.
Change in RKF will be determined using several 
methods. We will calculate, using linear regression anal-
ysis for individual subjects, rate of decline in GFR (mean 
of urea and creatinine clearance) for individual subjects 
and compare means of these rates between incremental 
and conventional HD groups with a t test if normally 
distributed. This effect size will be important in powering 
future definitive trials. Using a previously described 
method we will employ a mixed- effects model to compare 
rate of decline in GFR between randomisation groups.28 
As an indicator of RKF, we will compare urine volume data 
between groups using similar statistical techniques to the 
above. We will also compare proportions of patients in the 
two groups who have a residual interdialytic urea clear-
ance ≥2 and ≥3 mL/min/1.73 m2 at 6 months. In addi-
tion, we will estimate RKF (GFR) from monthly measured 
predialysis middle molecule concentrations of β trace 
protein and β2- microglobulin converted to an equivalent 
GFR using the algorithm reported by Wong et al.31 We will 
calculate rate of decline in GFR for individual patients 
from these middle molecule concentrations and using 
regression analysis for individual patient data to deter-
mine GFR slope and will compare mean slope between 
incremental HD and standard care groups.
Data from the EQ- 5D- 5L, PHQ-9, MoCA, IIRS and 
CFS will be compared between study arms with repeated 
measures parametric or non- parametric tests as appro-
priate (repeated measures analysis of variance or 
Friedman tests). Comparison of MACE, vascular access 
events (access failure, access intervention, access related 
infections, fistula stenosis and fistula thrombosis), hyper-
kalaemic episodes, fluid overload episodes and lower 
respiratory tract infection episodes will be compared 
between groups using time- to- event analysis by the 
Nelson- Aalen approach.
DISCUSSION
Clinical practice guidelines for HD adequacy, update 
200632 suggests that reduction of treatment frequency 
to less than thrice- weekly should only be considered 
in patients with interdialytic urea clearance >2 mL/
min/1.73 m2 since urea kinetic modelling simulations 
have shown that when residual urea clearance is less than 
this, it is not possible to achieve a weekly Std Kt/V of 2.0 
with twice- weekly dialysis regimens. Hence in this study, 
we have opted for a required interdialytic urea clearance 
(RKF) of ≥3 mL/min/1.73 m2 BSA prior to randomisa-
tion as an inclusion criterion to provide a safety margin.
There are a large number of observational studies5–18 
that compare clinical outcomes of patients treated with 
twice- weekly HD with those on conventional thrice- weekly 
HD regimens but to date no RCT that compare clinical 
outcomes of incremental or infrequent HD versus conven-
tional thrice- weekly HD have been published. Though 
these studies suggest that the rate of decline of RKF is 
slower using infrequent and incremental HD regimens 
but prospective, randomised data are not available. Hence 
it is unclear to what extent the benefits of incremental 
and infrequent HD are due to patient selection. Similarly, 
there are no comparative data on quality of life measures 
or on patient experience in conventional versus incre-
mental HD. Mortality risk and survival outcomes have not 
been reported to be worse in patients treated with twice- 
weekly dialysis sessions9 13 16 and a large US study found 
that mortality risk was lower in prevalent patients treated 
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Hence there is a need for a definitive trial of incremental 
versus conventional dialysis initiation to define the effects 
on RKF preservation and patient- reported outcome and 
experience.
The outcome data of this current study will be used to 
inform the design of such a future definitive study. The 
proposed feasibility study will test assumptions around 
the effect size, the eligibility for screening, recruitability 
and retainability. Deviations from the assumed values 
will alter the design of the definitive study, for example, 
number of centres required, eligibility criteria, primary 
outcome measure, sample size and may indicate that a 
definitive study is non- viable.
It is likely that the outcomes of a definitive study will be 
important, not only in defining the potential benefit of 
incremental HD for patients, but in establishing whether 
such an approach may allow optimisation of resource use. 
If dialysis intensity can be reduced for patients with suffi-
cient RKF with patient benefit, this will liberate dialysis 
resources that may permit other patients with high dial-
ysis requirements to dialyse more frequently.
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